logo
Plus   Neg
Share
Email

Adidas Q3 Profit Down 1.8%; Confirms Full-year Outlook - Quick Facts

Adidas (ADDYY.PK,ADDDF.PK) reported that its third-quarter net income attributable to shareholders decreased 1.8 percent to 646 million euros from 658 million euros in the prior year. But, earnings per share were 3.27 euros, same with last year.

"We confirm our full-year outlook and remain confident about a significant top-line acceleration during the fourth quarter. 2019 will be a record year, despite some challenges, and another important milestone toward achieving our 2020 targets," said Kasper Rorsted, Adidas CEO.

Net income from continuing operations for the third-quarter decreased about 2% to 644 million euros from last year's 656 million euros. The latest-quarter result included a negative impact from the adoption of IFRS 16 of 15 million euros, reducing year-over-year net income growth by about 2 percentage points.

But, quarterly revenues grew 9.1% to 6.41 billion euros from 5.87 billion euros in the prior year.

Currency-neutral revenues for the quarter grew 6%. Revenues at the adidas brand also increased 6%. This improvement reflected high-single-digit growth in Sport Performance, driven by increases in the training, running and outdoor categories.

For 2019, the company continues to expect sales to increase at a rate of between 5% and 8% on a currency-neutral basis with a significant sequential top-line acceleration during the fourth quarter. Net income from continuing operations is projected to increase to a level between 1.88 billion euros and 1.95 billion euros, reflecting an increase of between 10% and 14% compared to the prior year level of 1.709 billion euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT